SEC Form 4 · accession 0000899243-18-002329
Seres Therapeutics, Inc. · MCRB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas DesRosier
Officer — See Remarks
Period of report
Jan 26, 2018
Accepted (ET)
Jan 30, 2018 · 8:58 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001609809
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| COMMON STOCKF1 | Jan 26, 2018 | M | 10,000 | — | A | 10,000 | D | |
| COMMON STOCK | Jan 26, 2018 | S | 3,475 | $11.02 | D | 6,525 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| RESTRICTED STOCK UNITSF1,F2 | — | Jan 26, 2018 | M | 10,000 | D | — | — | COMMON STOCK | 10,000 | 40,000 | D |
| STOCK OPTION (RIGHT TO BUY)F3 | $10.42 | Jan 30, 2018 | A | 80,000 | D | — | Jan 29, 2028 | COMMON STOCK | 80,000 | 80,000 | D |
| STOCK OPTION (RIGHT TO BUY)F4 | $10.42 | Jan 30, 2018 | A | 100,000 | D | — | Jan 29, 2028 | COMMON STOCK | 100,000 | 100,000 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
- F2These restricted stock units have vested and settled or will vest and settle as to 20% of the restricted stock units on January 26, 2018, 30% on January 26, 2019; and 50% on January 26, 2020.
- F3This Option will vest as to 25% of the shares on January 30, 2019. The remainder of the shares will vest in 12 equal quarterly installments thereafter.
- F4This Option will vest as to one third of the shares on January 30, 2019, one third on January 30, 2020 and one third on January 30, 2021.
Remarks
Chief Legal Officer and EVP